Ponatinib
- Generic Name
- Ponatinib
- Brand Names
- Iclusig
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F3N6O
- CAS Number
- 943319-70-8
- Unique Ingredient Identifier
- 4340891KFS
- Background
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
- Indication
1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病（CML）；或不能耐受达沙替尼或尼洛替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。
2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病（Ph+ALL）；或不能耐受达沙替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Antonio Fojo
- Registration Number
- NCT03838692
Study in Patients With Chronic Leukemia
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 18
- Registration Number
- NCT03807479
- Locations
- 🇩🇪
University Hospital, Halle (Saale), Saxony-Anhalt, Germany
🇩🇪University Hospital RWTH Aachen,Clinic for Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Department IV, Aachen, Germany
🇩🇪Asklepios Clinic St. Georg - Department of Oncology, Section Hematology, Hamburg, Germany
Iclusig PMS in CML or Ph+ALL Patients
- Conditions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03709017
- Locations
- 🇰🇷
Kosin University Gaspel Hospital, Busan, Korea, Republic of
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 245
- Registration Number
- NCT03589326
- Locations
- 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
🇨🇦Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada
🇧🇬University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveBCR-ABL1 Fusion Protein ExpressionRefractory Acute Lymphoblastic Leukemiat(9;22)
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT03263572
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03147612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02829840
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT02776605
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT02478164
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 283
- Registration Number
- NCT02467270
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada
🇬🇧Imperial College Healthcare NHS Trust, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.